Cogent Biosciences Inc
COGT
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.65B
Close$
$0.87
98% downside
Current Fair Value
98% downsideOvervalued by 98% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.65 Billion |
|---|---|
| Enterprise Value | $6.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.55 |
| Beta | 0.34 |
| Outstanding Shares | 67,414,000 |
Return
| Return on Equity | -58.30% |
|---|---|
| Return on Assets | -39.24% |
| Return on Invested Capital | -43.44% |
Valuation & Multiples
| P/E Ratio | -12.64 |
|---|---|
| PEG | -35.87 |
| Price to Sales | - |
| Price to Book Ratio | 4.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -18.11 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$1,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 59.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.28%▼ 267.36% |
|---|---|
| Total Invested | $216.02M▼ 96.99% |
| Investors Holding | 47▼ 270.00% |
ESG Score
No data
About Cogent Biosciences Inc
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently ...